Vento, Joseph
Mulgaonkar, Aditi
Woolford, Layton
Nham, Kien
Christie, Alana
Bagrodia, Aditya
de Leon, Alberto Diaz
Hannan, Raquibul
Bowman, Isaac
McKay, Renee M.
Kapur, Payal
Hao, Guiyang
Sun, Xiankai
Brugarolas, James
Funding for this research was provided by:
V Foundation Translational Award (T2018-011, T2018-011, T2018-011)
CPRIT funding (RP110771)
National Institutes of Health (P50196516)
National Institutes of Health (P50196516)
National Cancer Institute (1P30 CA142543)
Article History
Received: 8 February 2019
Accepted: 2 May 2019
First Online: 3 June 2019
Ethics approval and consent to participate
: All murine tumorgraft experiments were executed in compliance with institutional guidelines after approval of the institutional review board with protocol numbers 2015–100932, “Exploring RCC Genetics and Treatment Using Mouse Models,” and 2016–101458-CORE, “PET/CT Imaging of Normal or Diseased Mice with Radiotracers Developed or Produced by the Cyclotron and Radiochemistry Facility.” The mice described implanted are 4–6 week old male NOD-SCID (NOD.CB17-PrkdcSuperscript removed) mice.
: Written informed consent for publication of their clinical details and clinical images was obtained from the patient.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.